Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$77.93 USD

77.93
3,238,557

-0.68 (-0.87%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $77.93 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

by Zacks Equity Research

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.

Urmimala Biswas headshot

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

by Urmimala Biswas

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.

Zacks Equity Research

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

Zacks Equity Research

Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth

by Zacks Equity Research

Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.

Zacks Equity Research

Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss

by Zacks Equity Research

Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.

Zacks Equity Research

PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.

Zacks Equity Research

AMN Healthcare (AMN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Nurse and Allied Solutions segment drives AMN Healthcare's (AMN) third-quarter results.

Zacks Equity Research

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.

Zacks Equity Research

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

We are encouraged to note that NuVasive (NUVA) witnessed solid revenue growth across its U.S. Spinal Hardware business in Q3.

Zacks Equity Research

Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet

by Zacks Equity Research

Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

Zacks Equity Research

IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View

by Zacks Equity Research

IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.

Zacks Equity Research

CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.

Zacks Equity Research

Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

Zacks Equity Research

PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

Zacks Equity Research

ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2

by Zacks Equity Research

Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.

Zacks Equity Research

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

by Zacks Equity Research

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Zacks Equity Research

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

by Zacks Equity Research

Masimo (MASI) raises its 2019 product revenue guidance.

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

by Urmimala Biswas

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Zacks Equity Research

Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.

Zacks Equity Research

McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat

by Zacks Equity Research

McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.

Zacks Equity Research

Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.

Zacks Equity Research

Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat

by Zacks Equity Research

Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

Zacks Equity Research

Has Edwards Lifesciences (EW) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (EW) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1

by Zacks Equity Research

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Zacks Equity Research

Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

by Zacks Equity Research

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.